ATP-competitive inhibitors midostaurin and avapritinib have distinct resistance profiles in exon 17-mutant KIT

KIT is a type-3 receptor tyrosine kinase that is frequently mutated at exon 11 or 17 in a variety of cancers. First generation KIT tyrosine kinase inhibitors (TKIs) are ineffective against KIT exon 17 mutations, which favor an active conformation that prevents these TKIs from binding. The ATP-compet...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Res
Päätekijät: Winger, Beth Apsel, Cortopassi, Wilian A., Ruiz, Diego Garrido, Ding, Lucky, Jang, Kibeom, Leyte-Vidal, Ariel, Zhang, Na, Esteve-Puig, Rosaura, Jacobson, Matthew P., Shah, Neil P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2019
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6697585/
https://ncbi.nlm.nih.gov/pubmed/31270078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-3139
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia